| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/04/2002 | CN1090235C Method for purifying viruses by chromatography |
| 09/04/2002 | CN1090234C Analgesic health-care soap |
| 09/04/2002 | CN1090030C Complex cow's milk gamma globulin and making method thereof |
| 09/04/2002 | CN1090029C Combinations of thrombolytically active proteins and anticoagulants, and uses thereof |
| 09/04/2002 | CN1090022C Cancer treatment by photodynamic therapy, in combination with immunoadjuvant |
| 09/04/2002 | CN1090021C Preparation method and use of sulfated oligosaccharides |
| 09/03/2002 | US6444871 Expression vector for use in the treatment and prevention of viral diseases |
| 09/03/2002 | US6444804 Proteins involved in the synthesis and assembly of core lipopolysaccharide of Pseudomonas aeruginosa |
| 09/03/2002 | US6444800 Human gastric cancer antigen gene and gastric cancer antigen protein |
| 09/03/2002 | US6444799 P. gingivalis polynucleotides and uses thereof |
| 09/03/2002 | US6444787 Vaccines |
| 09/03/2002 | US6444650 Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| 09/03/2002 | US6444642 Administering to mammal effective amount of neuregulin polypeptide with p185.sup.erbb2 protein binding activity to stimulate myogenesis of muscle cells |
| 09/03/2002 | US6444468 Treating a sample comprising different double-stranded template polynucleotides wherein said different template polynucleotides contain areas of identity and areas of heterology under conditions which provide for the cleavage of |
| 09/03/2002 | US6444446 Calcium binding proteolipid compositions and methods |
| 09/03/2002 | US6444445 Genetic engineering |
| 09/03/2002 | US6444444 Immunogenic composition, comprising at least one nucleic acid fragment as an active component thereof and vector for transformation of a host comprising the nucleic acid fragment |
| 09/03/2002 | US6444443 Gene |
| 09/03/2002 | US6444425 Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung |
| 09/03/2002 | US6444210 Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity |
| 09/03/2002 | US6444209 Hybrid botulinal neurotoxins |
| 09/03/2002 | US6444208 Ribonuclease III from Streptococcus pneumoniae |
| 09/03/2002 | US6444207 Binding with epitope of antigen; anticancer agents |
| 09/03/2002 | US6444206 Sepsis therapy; monoclonal antibodies |
| 09/03/2002 | CA2160764C Fish pancreatic disease virus |
| 09/03/2002 | CA2093557C Antimicrobial composition |
| 08/29/2002 | WO2002066980A1 Methods for immuno-detection of epitopes on molecules and for detection of interactions of molecules via fluorescent dyes |
| 08/29/2002 | WO2002066979A1 Method of detecting antigen causative of bronchial asthma |
| 08/29/2002 | WO2002066652A2 Ehrlichia ruminantium polypeptides, antigens, polynucleotides, and methods of use |
| 08/29/2002 | WO2002066650A2 Streptococcus pyogenes polypeptides and corresponding dna fragments |
| 08/29/2002 | WO2002066649A2 ANTI-INTERFERON-α ANTIBODIES |
| 08/29/2002 | WO2002066647A2 Type 2 ctokine receptor and nucleic acids encoding same |
| 08/29/2002 | WO2002066629A2 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| 08/29/2002 | WO2002066627A1 Regulation of human dipeptidyl peptidase 8 |
| 08/29/2002 | WO2002066621A1 Attenuated live vaccine |
| 08/29/2002 | WO2002066619A1 Methods of treating inflammation, particularly diabetes |
| 08/29/2002 | WO2002066605A2 Compositions and methods relating to breast specific genes and proteins |
| 08/29/2002 | WO2002066516A2 Antibodies that bind both bcma and taci |
| 08/29/2002 | WO2002066509A2 Treatment involving dkk-1 or antagonists thereof |
| 08/29/2002 | WO2002066506A2 Use of casb7439 (ash2) in the immunotherapy of breast cancer |
| 08/29/2002 | WO2002066503A2 H. influenzae antigen basb213 |
| 08/29/2002 | WO2002066501A2 PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI) |
| 08/29/2002 | WO2002066488A1 Compositions and methods relating to prostate specific genes and proteins |
| 08/29/2002 | WO2002066077A2 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066058A1 Modified anti-egfr antibodies with reduced immunogenicity |
| 08/29/2002 | WO2002066057A2 Methods and compositions for preventing and treating neutrophil-mediated diseases |
| 08/29/2002 | WO2002066056A2 Synthetic vaccines comprising polyhydroxypolymer carriers |
| 08/29/2002 | WO2002066055A1 NOVEL MEDICINAL USE OF α ANTIGEN OR α ANTIGEN GENE |
| 08/29/2002 | WO2002066054A1 Vaccine to protect animals against leishmania |
| 08/29/2002 | WO2002066053A2 Method of treating or preventing disease characterized by cryptococcus neoformans infection |
| 08/29/2002 | WO2002066044A2 Method for dendritic cells based immunotherapy of tumors using combination therapy |
| 08/29/2002 | WO2002066005A1 Composition and method for controlled release injections |
| 08/29/2002 | WO2002065992A2 A cell therapy method for the treatment of tumors |
| 08/29/2002 | WO2002050108A3 Immunogenic glycopeptides, screening, preparation and uses |
| 08/29/2002 | WO2002033112A3 Protein-protein interactions in neurodegenerative diseases |
| 08/29/2002 | WO2002028422A3 Split enveloped virus preparation for intranasal delivery |
| 08/29/2002 | WO2002022795A3 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2002016409A3 Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
| 08/29/2002 | WO2002010403A3 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 08/29/2002 | WO2002010388A3 C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF |
| 08/29/2002 | WO2002004018A3 Mid-life vaccine and methods for boosting anti-mycobacterial immunity |
| 08/29/2002 | WO2002003917A3 Alphavirus vectors and virosomes with modified hiv genes for use as vaccines |
| 08/29/2002 | WO2002002141A3 Vaccine against helicobacter pylori |
| 08/29/2002 | WO2001091808A3 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 08/29/2002 | WO2001080888A3 Method for treatment of tumors using photodynamic therapy |
| 08/29/2002 | WO2001068858A3 Human g protein-coupled receptors |
| 08/29/2002 | WO2001068053A3 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 08/29/2002 | WO2001061055A3 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes |
| 08/29/2002 | WO2001016174A9 Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65 |
| 08/29/2002 | WO2001007481A9 Antitumor antibodies, proteins, and uses thereof |
| 08/29/2002 | WO2001005427A9 Psca: prostate stem cell antigen and uses thereof |
| 08/29/2002 | WO2000063245A9 Variant of the plasmodium merozoite surface protein (msp-1) and vaccine comprising said variant |
| 08/29/2002 | WO2000059515A9 Immunomodulating polymers |
| 08/29/2002 | WO2000056866A9 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 08/29/2002 | WO2000037502A9 Vascular endothelial cell growth factor antagonists and uses thereof |
| 08/29/2002 | WO2000034474A9 Growth factor homolog zvegf3 |
| 08/29/2002 | WO2000034447A9 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 08/29/2002 | WO1999057280A9 Neisseria meningitidis antigens and compositions |
| 08/29/2002 | US20020120123 Human vascular endothelial growth factor 2 |
| 08/29/2002 | US20020120115 Isolated polynucleotide encoding an outer membrane protein of Ehrlichia canis; immunoassay; vaccines; diagnostic kits |
| 08/29/2002 | US20020120106 Peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating immune response; antisense agents |
| 08/29/2002 | US20020120103 17 human secreted proteins |
| 08/29/2002 | US20020119940 Gene expression and delivery systems and uses |
| 08/29/2002 | US20020119927 Protein-protein interactions in neurodegenerative diseases |
| 08/29/2002 | US20020119926 Inhibitors of IAPP fibril formation and uses thereof |
| 08/29/2002 | US20020119571 Stimulating lymphocytes of graft recipient by cells of graft donor or by cells expressing dominant Major Histocompatability Complex-molecules while transduced with immunmodulatory genes using gene transfer; prevents rejection of allogeneic grafts |
| 08/29/2002 | US20020119565 Isolation and use of solid tumor stem cells |
| 08/29/2002 | US20020119554 Arginase II |
| 08/29/2002 | US20020119529 Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220 |
| 08/29/2002 | US20020119527 Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
| 08/29/2002 | US20020119517 Detection of modulators of body weight; obtain cell samples, monitor expression of preferenial genes, incubate with modulators, compare to control, monitor adjustment in body weight |
| 08/29/2002 | US20020119504 Antibody or antigen-binding sequences for use in the treatment of inflammatory bowel disease |
| 08/29/2002 | US20020119495 Immunogenic composition of hepatitis C and methods of use thereof |
| 08/29/2002 | US20020119492 Modulating immunogenicity of a target protein; obtain protein sequence, record in computer, screen library for preferental amino acid sequences |
| 08/29/2002 | US20020119447 Non-a,non-b,non-c,non-c,non-d,non-e hepatitis reagents and methods for their use |
| 08/29/2002 | US20020119445 Genetic engineering; prophylactic therapy |
| 08/29/2002 | US20020119189 Nucleosome-based anti-tumor compositions |
| 08/29/2002 | US20020119166 For inducing active immunity to infections caused by Staphylococcus aureus, S. epidermidis |
| 08/29/2002 | US20020119163 Methods and compositions for protection against bovine viral deseases |